Management of adverse events associated with idelalisib treatment: expert panel opinion

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing informati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Lymphoma
Hlavní autoři: Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2015
Témata:
Reviews
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4732460/
https://ncbi.nlm.nih.gov/pubmed/25726955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1022770
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky